These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 1416572

  • 1. Octreotide treatment of acromegaly. A randomized, multicenter study.
    Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, Molitch ME, Boyd AE, Sheeler L, Cook DM.
    Ann Intern Med; 1992 Nov 01; 117(9):711-8. PubMed ID: 1416572
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY, Weissberger AJ, Marbach P, Lazarus L.
    Ann Intern Med; 1990 Feb 01; 112(3):173-81. PubMed ID: 2404445
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB, Melmed S, Snyder PJ, Young WF, Boyajy LD, Levy R, Stewart WN, Klibanski A, Molitch ME, Gagel RF.
    J Clin Endocrinol Metab; 1995 Sep 01; 80(9):2768-75. PubMed ID: 7673422
    [Abstract] [Full Text] [Related]

  • 5. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I, De Boisvilliers F, Chanson P, Lucas B, DeWailly D, Catus F, Thomas F, Jaquet P.
    J Clin Endocrinol Metab; 1994 Jul 01; 79(1):145-51. PubMed ID: 8027218
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ, Emery M, Howling SJ, Evanson J, Besser GM, Monson JP.
    Horm Res; 2004 Jul 01; 62(5):227-32. PubMed ID: 15477693
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Octreotide in the management of active acromegaly due to inoperable growth hormone-secreting adenoma.
    Candrina R.
    Recenti Prog Med; 1994 Jan 01; 85(1):13-9. PubMed ID: 8184174
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
    Riedel M, Günther T, von zur Mühlen A, Brabant G.
    Clin Endocrinol (Oxf); 1992 Sep 01; 37(3):233-9. PubMed ID: 1358484
    [Abstract] [Full Text] [Related]

  • 20. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.
    Hansen TB, Gram J, Bjerre P, Hagen C, Bollerslev J.
    Clin Endocrinol (Oxf); 1994 Sep 01; 41(3):323-9. PubMed ID: 7955439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.